Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
2.
Microorganisms ; 9(6)2021 Jun 13.
Artículo en Inglés | MEDLINE | ID: covidwho-1270087

RESUMEN

BACKGROUND: The disease severity, ranging from being asymptomatic to having acute illness, and associated inflammatory responses has suggested that alterations in the gut microbiota may play a crucial role in the development of chronic disorders due to COVID-19 infection. This study describes gut microbiota dysbiosis in COVID-19 patients and its implications relating to the disease. DESIGN: A cross sectional prospective study was performed on thirty RT-PCR-confirmed COVID-19 patients admitted to the All India Institute of Medical Sciences, Bhopal, India, between September 10 and 20, 2020. Ten healthy volunteers were recruited as the control group. IFN, TNF, and IL-21 profiling was conducted using plasma samples, and gut bacterial analysis was performed after obtaining the metagenomics data of stool samples. RESULTS: Patients with a variable COVID-19 severity showed distinct gut microflora and peripheral interleukin-21 levels. A low Firmicute/Bacteroidetes ratio, caused by the depletion of the fibre-utilizing bacteria, F. prausnitzii, B. Plebius, and Prevotella, and an increase in Bacteroidetes has associated gut microbiota dysbiosis with COVID-19 disease severity. CONCLUSIONS: The loss of the functional attributes of signature commensals in the gut, due to dysbiosis, is a predisposing factor of COVID-19 pathophysiology.

3.
Iran J Immunol ; 18(1): 1-12, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: covidwho-1160970

RESUMEN

Severe Acute Respiratory Syndrome (SARS) associated with SARS-CoV-2, causes a severe form of the respiratory illness known as Coronavirus Disease-19 (COVID-19). COVID-19 has emerged as a worldwide pandemic with a high number of fatalities. Approximately 112,654,202 people have been infected so far with this disease which has led to the death of more than one point seven million (2,496,749) till 24th Feb, 2021. Measures to counter this disease have led to a global economic slowdown. Multiple drug trials are ongoing and several putative candidates for vaccination against the virus have been approved and are in the pipeline. Many studies have also characterized the immunological profile of patients infected with COVID-19. Some studies suggest that the severity of the COVID-19 infection is directly associated with the cytokine storm. In this review, we aim to compile the available knowledge and describe the nature of immune responses in patients infected with COVID-19 in different age groups, comorbidity, and immune-compromised state and their association with disease severity.


Asunto(s)
Inmunidad Adaptativa , COVID-19/inmunología , Inmunidad Innata , SARS-CoV-2/inmunología , Inmunidad Adaptativa/efectos de los fármacos , Factores de Edad , Antivirales/uso terapéutico , COVID-19/mortalidad , COVID-19/terapia , COVID-19/virología , Vacunas contra la COVID-19/uso terapéutico , Comorbilidad , Síndrome de Liberación de Citoquinas/inmunología , Síndrome de Liberación de Citoquinas/virología , Interacciones Huésped-Patógeno , Humanos , Inmunidad Humoral , Inmunidad Innata/efectos de los fármacos , Huésped Inmunocomprometido , Pronóstico , Medición de Riesgo , Factores de Riesgo , Índice de Severidad de la Enfermedad , Tratamiento Farmacológico de COVID-19
4.
Dig Dis ; 39(1): 66-67, 2021.
Artículo en Inglés | MEDLINE | ID: covidwho-846549
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA